Skip to content

KRRO: Held by 6 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Korro Bio, Inc. (KRRO)

Korro Bio, Inc.

KRRO

Held by 6 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

6 funds opened new positions. Next phase2 readout (KRRO-121): Aug 2027. Short interest: 11.5% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Ram AiyarIPO: 2019Website ↗

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.5/10

6 funds opened new positions●●

No recent insider activity●●

Phase2 readout expected Aug 2027●●

Held by 6 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

6 specialist funds hold KRRO with a Phase 2 in 368 days for KRRO-121 (Urea Cycle Disorders, Inborn, Urea Cycle Disorders, Ornithine Transcarbamylase (OTC) Deficiency)

Rock Springs Capital Driehaus Capital Cormorant Asset Management OrbiMed Advisors Deep Track Capital Eventide Asset Management

Fund Holdings

6 fund convergence

Rock Springs Capital

Driehaus CapitalHeld 2Q

Cormorant Asset Management

OrbiMed Advisors

Deep Track Capital

Eventide Asset Management

Position history (shares)

Rock Springs Capital

5Q

Driehaus Capital

7Q

Cormorant Asset Management

4Q

OrbiMed Advisors

4Q

Deep Track Capital

4Q

Eventide Asset Management

2Q

AI Signal

Eventide Exit — KRRO

Eventide has fully exited Korro Bio, a notable departure given the firm's history of holding early-stage genomic medicine names through extended development timelines. The exit stands in contrast to continued ownership by six specialist biotech funds — Cormorant, Driehaus, Rock Springs, Deep Track, and OrbiMed — whose collective retention signals sustained conviction in Korro's adenine base editing platform targeting cardiovascular and cardiometabolic indications (lead program KRRO-110 in AATD).

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Feb 13, 2026

$0

0 funds

Feb 17, 2026

$0

0 funds

May 15, 2026

$5.1M

1 fund

Aug 14, 2026

$5.9M

1 fund

-77% total institutional value over 15 quarters

Short Interest

Float data divergenceHigh short interest

Short Shares

1.51M

Change

+3.6%

Days to Cover

10.9

% of Float

11.5%

Settlement

Aug 14, 2026

Short interest over 12 periods

Catalysts

Phase 2NegativeQ4 2025KRRO-110Alpha-1 Anti-trypsin Deficiency, AATDNCT06677307

Phase 2Q3 2027KRRO-121Urea Cycle Disorders, Inborn, Urea Cycle Disorders, Ornithine Transcarbamylase (OTC) DeficiencyNCT07773246

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ADriehaus Capital0.0%Feb 17, 2026

SC 13G/ADriehaus Capital7.2%Nov 14, 2025

SC 13G/ADeep Track Capital3.0%Aug 14, 2025

SC 13GDriehaus Capital5.3%Feb 14, 2025

SC 13G/AEventide Asset Management4.2%Nov 14, 2024

SC 13G/ACormorant Asset Management2.9%Nov 14, 2024

SC 13G/ADeep Track Capital9.1%Nov 14, 2024

SC 13GDeep Track Capital7.7%Apr 26, 2024

SC 13G/ACormorant Asset Management3.9%Feb 14, 2024

SC 13GEventide Asset Management6.8%Feb 14, 2024

SC 13GCormorant Asset Management5.8%Nov 16, 2023

Position Details

Rock Springs CapitalEXITEDAug 14, 2026

Start free trialfor share counts, dollar values & AI analysis

55 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

COGT1 fund CMPS1 fund CRBP1 fund STTK1 fund SPRY1 fund AORT1 fund ASND1 fund AZN1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: